Latest news with #Bischof
Yahoo
5 days ago
- Sport
- Yahoo
Bayern Munich has signed Tom Bischof, but where exactly will he play?
Bayern Munich has been linked to Tom Bischof since his days in Hoffenheim's youth setup, and his transfer to Bayern Munich was announced six months ago. Despite not yet having played a match for Bayern, many fans are already quite familiar with the player. Once touted as the next big attacking midfielder in German football, questions were raised as to how Bischof might one day fit in at Bayern Munich with the likes of Jamal Musiala vying for the same position. At the time, Thomas Müller was also seen as an obstacle to get past if a player in that position was to find his way into the starting eleven. Advertisement Given time, the Bischof positional problem seems to have solved itself. As captured by @iMiaSanMia, Bischof shared his positional journey over the years, saying: 'I used to play in a more attacking position. Now, at [the] professional level, playing at #6 and #8 has been very beneficial for me. I feel comfortable everywhere centrally. But I see myself at #6 and #8.' So, problem solved, right? Well, not exactly. Bayern Munich isn't short of quality options in the #6 or #8 roles either, with Joshua Kimmich, Leon Goretzka, Aleksandar Pavlović, João Palhinha, Konrad Laimer, and even Raphaël Guerreiro having occupied at least one of those roles in recent years. Fans have even seen players like Ryan Gravenberch and Angelo Stiller move on due to a lack of first-team minutes. If Bischof wants any serious playing time next season, he's going to have to really impress Vincent Kompany and the coaching staff at Bayern Munich. More from
Qatar Tribune
6 days ago
- Sport
- Qatar Tribune
Talent Bischof raring to go as he names Bayern move ‘perfect match'
dpa Orlando, Florida Teenager Tom Bischof has named his move to Bundesliga champions Bayern Munich 'a perfect match' and does not mind being compared to Bayern and Germany great Joshua Kimmich. The 19-year-old Bischof arrived on a free transfer from Hoffenheim and could make his debut on Sunday in their Club World Cup opener against Auckland City in Cincinnati. That would be a week after he got his first minutes for the senior national team in the Nations League match for third place against France, underlining his meteoric rise over the past months. Bischof said at his official presentation at Bayern's camp in Florida that he has been a life-long Bayern fan, and happy to play at the Club World Cup instead of the under-21 Euros in Slovakia. 'We are together here for a month. Of course the U21 Euros are something great. (But) I want to find my feet in the team, produce great performances and win trophies. I'm raring to go,' he said. Bischof said that other clubs were also interested in him but that 'the talks with (board member for sport) Max Eberl, (sporting director) Christoph Freund and also (coach) Vincent Kompany were very good. The system of play suits me very well.' Freund named Bischof 'a really talented player' who 'suits FC Bayern very well with the way he plays.' Bischof joins an already crowded Bayern midfield where he will be competing with fellow German internationals Leon Goretzka and Aleksandar Pavlovic as well as Portugal's João Palhinha for playing time alongside national team captain Kimmich. Bischof has been compared to Kimmich by the likes of 1990 World Cup winner and ex-Bayern great Lothar Matthäus. 'I have heard the comparison a few times. Jo is an outstanding footballer. I look up to him. And I do believe that our style is similar. But of course I want to play together with him in the centre (of midfield),' Bischof said.
Yahoo
09-06-2025
- Sport
- Yahoo
Bayern seal deal with Hoffenheim for Bischof to join Club World Cup squad
Bayern seal deal with Hoffenheim for Bischof to join Club World Cup squad Tom Bischof has been cleared to represent Bayern Munich at the upcoming Club World Cup. The Bavarians had already announced that the central midfielder would join on a free transfer from Hoffenheim, with his contract officially beginning on July 1. Advertisement However, according to Kicker, Bayern have now reached an agreement with Hoffenheim on a €300,000 transfer fee that allows the 19-year-old to join the squad early and take part in the tournament. The fee could increase through bonus payments if Bayern perform well in the competition, the report adds. Bischof, 19, made his senior debut for Germany in Sunday's 2–0 defeat to France.
Yahoo
09-06-2025
- Sport
- Yahoo
Report: Germany debutant Bischof to join Bayern for Club World Cup
(L-R) Germany's Tom Bischof, Thilo Kehrer, David Raum and Robin Koch in action during the final training session of the German national soccer team ahead of Wednesday's UEFA Nations League semi-final match against Portugal. Federico Gambarini/dpa Germany debutant Tom Bischof will reportedly be eligible to join Bayern Munich for the upcoming Club World Cup after the Bundesliga champions agreed to pay a fee to his previous club Hoffenheim. Kicker sports magazine said on Sunday night that Bayern will pay around €300,000 ($342,000) to have the teenager available before July 1. Advertisement The ruling body FIFA has a special transfer window running until Tuesday for the 32 clubs participating at the month-long tournament in the United States which kicks off on Saturday. Players contracts normally end on June 30 and start on July. Bayern have reportedly in a similar way secured the service of Germany defender Jonathan Tah, who arrives on a free transfer from Bayer Leverkusen. But in this case the fee is said to be up to €4 million. Bayern - who are yet to confirm the reports - play their first match at the Club World Cup on Sunday against Auckland City, with Boca Juniors and Benfica their other opponents in the group stage. Midfielder Bischof made his national team debut on Sunday when he came on in the 65th minute for future Munich team-mate in the Nations League match for third place which they lost 2-0 against France. Advertisement Coach Julian Nagelsmann named Bischof "a super lad, a very, very good character." He said it was also noted that Bischof helped the physios clean up their equipment, speaking of "small gestures which I take notice of." "I hope that he retains this normal, down-to-earth mentality" after the move to Munich, Nagelsmann said, speaking of "a very, very big" step. "He has a lot to offer and is a very, very fine footballer. Of course he still has steps to take. But after the week of training, he deserved his debut," Nagelsmann said. "My strong wish is that he stays as normal as possible. Then he also has a great chance of having a good career."
Yahoo
02-05-2025
- Business
- Yahoo
OCT Europe: Small and mid-sized sponsors demand smart and reliable partnerships
One of the key challenges in clinical trial operations today is maintaining a trustworthy and reliable relationship with partners, vendors, and sites, says Sarah Bischof, Head of Clinical Developments at invIOs, a private biotech company developing next-generation cancer therapies. At a closing panel discussion on the first day of the Outsourcing in Clinical Trials (OCT) Europe 2025 meeting, Dr. Claudia Hesselmann, Founder and CEO of ARENSIA, an early phase clinical trial partner, reproached the current inefficiencies in clinical trials. She stated that 'efficiency in clinical research could be improved at least by 80%' if only counterparts demonstrated greater initiative and accountability, actively questioning existing limitations rather than accepting established practices. In her opinion, one of the best regulatory environments to conduct clinical trials is Moldova, which has a ten day fast-track review timeline for clinical trials of all phases. As the Clinical Trials Information System (CTIS) portal was implemented in the European Union, the authorities in Moldova wanted to attract more clinical trials and drive innovation in the country and become as competitive as other countries such as Australia, said Hesselmann. Moldova's regulatory bodies are an example of how proactive agencies are essential to implement changes that can drive efficiencies, she said. While discussing their experience with CTIS, Bischof shared that when submitting trial protocols for immunotherapies and autologous cell therapy trials through the new EU Clinical Trials Regulation (CTR) with their contract research organisation (CRO), her team was faced with new administration and documentation burdens with new workflows, portals, and registration processes. With the new CTR implementation, Bischof observed lesser flexibility in terms of responding for trial sites and manufacturing because of the tight deadlines, such as twelve calendar days to provide the request for information. Data protection for confidential documentation with the new directive created a need to re-adapt trial strategies to redact and protect their data. Early preparation for CTIS submission is crucial because delays may lead to compliance issues, and the a cross-functional coordination of all teams from regulatory to legal is needed to meet these tight deadlines, Bischof shared. However challenging this was, Bischof stated that she would not go back to the old CTR directive because the timelines are more defined in this new directive, leading to improved trial planning. Still, companies without centralised clinical operations are finding it harder to adapt, and success depends on changes to internal processes, retraining teams, and updating document templates, she noted. Hesselmann highlighted that in her experience from the site's perspective, she has observed a dramatic difference in whether the sponsor has an operational team. 'The sponsor has a different approach to timelines because they own the compound, whereas the CRO does not,' said Hesselmann. In small to mid-sized biopharma companies, resources are limited; however, according to Hesselmann, even a single clinical trials operation leader from the sponsor side can make a meaningful difference in the smooth clinical trial execution. Diving into the topic of limited resources of small and mid-sized companies, both speakers acknowledged the high turnover rate amongst key project managers, scientists, and regulatory staff in the industry, which results in project disruption, uncertainty and disengagement. Hesselmann said that sites see a very high turnover rate, especially on the CRO side, with 'even three to four manager changes in one project,' which negatively affects the project continuity. 'Staff retention in the industry is a huge problem, not only on the programme manager level but even on the monitoring level', she added. In some cases, the dedication of the site staff and principal investigator (PI) hinge on the project leader's commitment. Bischof agreed that when faced with staff turnover as a small and mid-sized company, there is a need to redesign roles to encourage multi-skilling and cross-functional collaborations. Further, she noted that it is important to empower trans-functional market scaling strategies to the remaining team as well as to be agile and adapt fast in terms of structure and processes. The biggest operational challenge of small and mid-sized companies lies in the selection and management of CROs and other vendors as well as the implementation of patient-centric approaches. Hesselmann pointed out that 'the site should not be put in the unfortunate position of inviting patients for screening, only to send them home due to randomisation system failures or other technical or decisional issues caused by the sponsor, CRO, or vendors.' To conclude the panel, Bischof noted that external partnerships can temporarily ease the load with long-term headcount gaps and a transparent empathetic leadership can retain trust during transition periods, while Hesselmann stressed the importance of possessing a problem-solving mentality when faced with limited resources. The 15th Annual Outsourcing in Clinical Trials Europe took place in Barcelona, Spain from 29-30 April. "OCT Europe: Small and mid-sized sponsors demand smart and reliable partnerships" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
